ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
122.350,38
0,92%
S&P 500
5.996,66
1,00%
US Dollar vs BRL
6,08068
0,00%
Bitcoin
102.610,69
-1,46%
Brent Oil
80,005
0,00%
As Melhores Corretoras Online
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NYSE
  6. Qiagen NV (QGEN)

  7. Qiagen NV (QGEN) Notícias

QGEN

Qiagen NV (QGEN)

Qiagen NV
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NYSE:QGEN
DataHoraFonteTítuloCódigoCompanhia
16/01/202519:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:QGENQiagen NV
16/01/202518:05Business WireQIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $300 MillionNYSE:QGENQiagen NV
16/01/202518:05Business WireQIAGEN gibt Details zum Abschluss des synthetischen Aktienrückkaufs über bis zu rund $300 Mio. bekanntNYSE:QGENQiagen NV
15/01/202510:13Business WireQIAGEN N.V. to Release Results for Q4 2024 and Hold WebcastNYSE:QGENQiagen NV
12/01/202515:05Business WireQIAGEN to Return Approximately $300 Million to Shareholders Through a Synthetic Share RepurchaseNYSE:QGENQiagen NV
12/01/202515:05Business WireQIAGEN zahlt rund 300 Millionen Dollar durch einen synthetischen Aktienrückkauf an seine Aktionärinnen und Aktionäre zurückNYSE:QGENQiagen NV
10/01/202503:30Business WireTiefere Erkenntnisse aus biologischen Proben: QIAGEN erweitert digitales PCR-System QIAcuity um Multiplexing-Funktionen höherer OrdnungNYSE:QGENQiagen NV
10/01/202503:30Business WireQIAGEN Increases QIAcuity Digital PCR High-Order Multiplexing Capabilities to Gain Deeper Insights From Biological SamplesNYSE:QGENQiagen NV
09/01/202518:05Business WireQIAGEN secures U.S. clearance for first QIAstat-Dx mini gastrointestinal panel to support year-round outpatient careNYSE:QGENQiagen NV
09/01/202518:05Business WireQIAGEN erhält U.S.-Zulassung für erstes QIAstat-Dx Mini-Panel für Magen-Darm-Infektionen zur Unterstützung der ganzjährigen ambulanten VersorgungNYSE:QGENQiagen NV
07/01/202518:05Business WireQIAGEN liefert genomische Inhalte für britische Initiative zur Genomsequenzierung von 100.000 NeugeborenenNYSE:QGENQiagen NV
07/01/202518:05Business WireQIAGEN Supports UK Initiative to Sequence Genomes of 100,000 Newborns With Expert-Curated Genomic ContentNYSE:QGENQiagen NV
12/12/202418:05Business WireQIAGEN führt KI-Erweiterung für Ingenuity Pathway Analysis zur automatisierten Interpretation biologischer Daten einNYSE:QGENQiagen NV
12/12/202418:05Business WireQIAGEN Launches AI-Extension of Ingenuity Pathway Analysis for Automatic Interpretation of Biological DataNYSE:QGENQiagen NV
05/12/202418:05Business WireQIAGEN Reaches Milestone With Over 1,000 Placements of EZ2 Connect Sample Preparation Instrument, Driving Laboratory AutomationNYSE:QGENQiagen NV
05/12/202418:05Business WireQIAGEN erreicht Meilenstein: Über 1.000 platzierte EZ2 Connect-Systeme zur Probenvorbereitung treiben Laborautomatisierung voranNYSE:QGENQiagen NV
28/11/202408:00Business WireQIAGEN stärkt QIAstat-Dx mit neuem Standort in Barcelona zur Wachstumsbeschleunigung bei Tests für Infektionskrankheiten und PräzisionsmedizinNYSE:QGENQiagen NV
28/11/202408:00Business WireQIAGEN Strengthens QIAstat-Dx With New Barcelona Site to Drive Growth in Infectious Diseases and Precision Medicine TestingNYSE:QGENQiagen NV
27/11/202418:05GlobeNewswire Inc.QIAGEN launches novel tools for customizing digital PCR assays and NGS panels for microbial analysisNYSE:QGENQiagen NV
12/11/202418:05GlobeNewswire Inc.QIAGEN collaborates with McGill University to advance microbiome researchNYSE:QGENQiagen NV
07/11/202413:46Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNYSE:QGENQiagen NV
06/11/202418:05GlobeNewswire Inc.QIAGEN delivers solid Q3 2024 growth ahead of outlook, increases full-year 2024 adjusted EPS outlookNYSE:QGENQiagen NV
04/11/202403:30GlobeNewswire Inc.QIAGEN receives FDA clearance of QIAstat-Dx meningitis/encephalitis panel to support emergency diagnosticsNYSE:QGENQiagen NV
29/10/202403:30GlobeNewswire Inc.QIAGEN receives FDA clearance for QIAstat-Dx mini panel to improve precision in outpatient respiratory treatmentNYSE:QGENQiagen NV
10/10/202417:05GlobeNewswire Inc.QIAGEN expands automated liquid biopsy portfolio to enhance oncology, prenatal care and organ transplant applicationsNYSE:QGENQiagen NV
10/10/202408:41GlobeNewswire Inc.QIAGEN N.V. to release results for Q3 2024 and hold webcastNYSE:QGENQiagen NV
07/10/202417:05GlobeNewswire Inc.Global TB Summit 2024: QIAGEN leads the charge as tuberculosis reemerges as a leading infectious killerNYSE:QGENQiagen NV
30/09/202417:05GlobeNewswire Inc.QIAGEN launches QIAcuityDx digital PCR system for clinical testing in oncologyNYSE:QGENQiagen NV
26/09/202417:05GlobeNewswire Inc.QIAGEN receives European IVDR certification for QIAstat-Dx syndromic testing instruments and assaysNYSE:QGENQiagen NV
25/09/202417:05GlobeNewswire Inc.PreAnalytiX, a QIAGEN and BD joint venture, launches novel solution for liquid biopsy from urine samplesNYSE:QGENQiagen NV
 Apresentando as notícias mais relevantes sobre:NYSE:QGEN

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
BRAV3
Brava Energia ON
BOV
FNAM11
Fundo Invest Amazonia Fi...
BOV
AMOB3
Automob Participacoes ON
BOV
PMAM3
PARANAPANEMA ON
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
COGN3
COGNA ON
BOV
HBRE3
HBR Realty Empreendiment... ON
BOV
AMER3
Americanas ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados